HK1188145A1 - 作為酪蛋白激酶抑制劑的新型稠合吡啶化合物 - Google Patents

作為酪蛋白激酶抑制劑的新型稠合吡啶化合物

Info

Publication number
HK1188145A1
HK1188145A1 HK14101403.3A HK14101403A HK1188145A1 HK 1188145 A1 HK1188145 A1 HK 1188145A1 HK 14101403 A HK14101403 A HK 14101403A HK 1188145 A1 HK1188145 A1 HK 1188145A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
casein kinase
pyridine compounds
fused pyridine
novel fused
Prior art date
Application number
HK14101403.3A
Other languages
English (en)
Inventor
．巴特勒
．錢德拉塞卡蘭
．曼特
．薩布拉曼亞姆
．瓦格爾
Original Assignee
輝瑞大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 輝瑞大藥廠 filed Critical 輝瑞大藥廠
Publication of HK1188145A1 publication Critical patent/HK1188145A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
HK14101403.3A 2010-12-20 2014-02-14 作為酪蛋白激酶抑制劑的新型稠合吡啶化合物 HK1188145A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
PCT/IB2011/055489 WO2012085721A1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1188145A1 true HK1188145A1 (zh) 2014-04-25

Family

ID=45446116

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14101403.3A HK1188145A1 (zh) 2010-12-20 2014-02-14 作為酪蛋白激酶抑制劑的新型稠合吡啶化合物

Country Status (24)

Country Link
US (1) US8536164B2 (zh)
EP (2) EP2654750B1 (zh)
JP (2) JP5684923B2 (zh)
KR (1) KR101590236B1 (zh)
CN (1) CN103260622B (zh)
AR (1) AR084412A1 (zh)
AU (1) AU2011346733C1 (zh)
CA (1) CA2819961C (zh)
CY (2) CY1118772T1 (zh)
DK (2) DK3181133T3 (zh)
ES (2) ES2623387T3 (zh)
HK (1) HK1188145A1 (zh)
HR (2) HRP20170484T1 (zh)
HU (2) HUE032405T2 (zh)
IL (1) IL226948A (zh)
LT (2) LT2654750T (zh)
MX (1) MX338551B (zh)
PL (2) PL3181133T3 (zh)
PT (2) PT2654750T (zh)
RS (2) RS59098B1 (zh)
SG (1) SG190802A1 (zh)
SI (2) SI2654750T1 (zh)
WO (1) WO2012085721A1 (zh)
ZA (1) ZA201303453B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2460065T3 (es) * 2009-10-28 2014-05-13 Pfizer Inc. Derivados de imidazol como inhibidores de la caseína quinasa
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9475817B2 (en) * 2012-12-21 2016-10-25 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
WO2021190615A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
CN116171280A (zh) * 2020-09-17 2023-05-26 詹森药业有限公司 酪蛋白激酶1δ调节剂
KR20230069169A (ko) * 2020-09-17 2023-05-18 얀센 파마슈티카 엔.브이. 카제인 키나제 1 델타 조절제
WO2022127755A1 (en) * 2020-12-15 2022-06-23 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
BR9809147A (pt) * 1997-05-22 2000-08-01 Searle & Co Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis
AR029423A1 (es) * 1999-12-21 2003-06-25 Sugen Inc Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
SI1906965T1 (sl) 2005-06-22 2015-09-30 Chemocentryx, Inc. Azaindolne spojine in postopki uporabe
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
ES2460065T3 (es) * 2009-10-28 2014-05-13 Pfizer Inc. Derivados de imidazol como inhibidores de la caseína quinasa

Also Published As

Publication number Publication date
CY1122062T1 (el) 2020-11-25
EP2654750A1 (en) 2013-10-30
SI2654750T1 (sl) 2017-04-26
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
EP2654750B1 (en) 2017-03-08
EP3181133B1 (en) 2019-07-24
PL3181133T3 (pl) 2019-12-31
LT3181133T (lt) 2019-09-25
US20120157440A1 (en) 2012-06-21
AU2011346733B2 (en) 2015-08-13
AR084412A1 (es) 2013-05-15
RS59098B1 (sr) 2019-09-30
KR20130121126A (ko) 2013-11-05
DK2654750T3 (en) 2017-05-01
CY1118772T1 (el) 2017-07-12
WO2012085721A1 (en) 2012-06-28
HUE047089T2 (hu) 2020-04-28
KR101590236B1 (ko) 2016-01-29
DK3181133T3 (da) 2019-08-26
LT2654750T (lt) 2017-05-10
CN103260622A (zh) 2013-08-21
JP5684923B2 (ja) 2015-03-18
US8536164B2 (en) 2013-09-17
PT2654750T (pt) 2017-05-04
PT3181133T (pt) 2019-09-16
MX2013005833A (es) 2013-07-05
CA2819961C (en) 2015-08-18
ES2623387T3 (es) 2017-07-11
IL226948A (en) 2017-04-30
JP2014503544A (ja) 2014-02-13
SI3181133T1 (sl) 2019-10-30
CN103260622B (zh) 2015-05-13
HRP20170484T1 (hr) 2017-06-02
MX338551B (es) 2016-04-20
ZA201303453B (en) 2014-07-30
AU2011346733A1 (en) 2013-07-18
EP3181133A1 (en) 2017-06-21
ES2744099T3 (es) 2020-02-21
JP5876596B2 (ja) 2016-03-02
RS55897B1 (sr) 2017-08-31
CA2819961A1 (en) 2012-06-28
SG190802A1 (en) 2013-07-31
JP2015107992A (ja) 2015-06-11
PL2654750T3 (pl) 2017-07-31
AU2011346733C1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
HK1188145A1 (zh) 作為酪蛋白激酶抑制劑的新型稠合吡啶化合物
HK1192247A1 (zh) 作為激酶抑制劑的雜環化合物
HK1199203A1 (zh) 激酶抑制劑多晶體
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
PL2531501T3 (pl) Inhibitory kinazy 1 regulującej sygnał apoptotyczny
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201208489B (en) Fused bicyclic kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1201271A1 (zh) 激酶抑制劑多晶型物
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
ZA201401416B (en) Novel rock kinase inhibitors
HK1209316A1 (zh) 取代的吡啶酰胺激酶抑制劑
GB201109162D0 (en) Casein kinase 1Delta (CK1Delta) inhibitors
GB201021161D0 (en) Casein kinase 1delta (CK1Delta) inhibitors
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101823D0 (en) Novel heterocyclic compounds 4
GB201101822D0 (en) Novel heterocyclic compounds 2
GB201101821D0 (en) Novel heterocyclic compounds 1